Vascular protection and regenerative effects of intranasal DL-3-N-butylyphthalide treatment after ischaemic stroke in mice

Mengyao Qu, Jingjie Zhao, Yingying Zhao, Jinmei Sun, Liping Liu, Ling Wei, Yongbo Zhang

ABSTRACT

Objective To investigate the effects of DL-3-N-butylyphthalide (NBP) via intranasal delivery after ischaemic stroke in mice.

Methods C57BL/6 mice were divided into three groups: sham, stroke with vehicle and stroke with NBP treatment. Ischaemic stroke was induced by permanent ligation of right middle cerebral artery with 7 min common carotid artery occlusion. NBP (100 mg/kg) or vehicle was intranasally administered at 1 hour after stroke and repeated once a day until sacrifice. Bromodeoxyuridine (BrdU) (50 mg/kg/day) was given from the third day until sacrifice. Sensorimotor function was tested during 1–21 days after stroke. Local cerebral blood flow in the ischaemic and peri-infarct regions was measured using laser Doppler flowmetry before, during and 3 days after ischaemia. Expressions of vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase as well as regenerative marker BrdU in the peri-infarct region were analysed by western blotting and immunohistochemical methods.

Results Compared with the vehicle group, NBP treatment significantly increased the VEGF expression in the poststroke brain. Stroke mice that received NBP showed significantly less vascular damage after stroke and more new neurons and blood vessels in the peri-infarct region at 21 days after stroke. In the adhesive removal test, the sensorimotor function of stroke mice treated with NBP performed significantly better at 1, 3 and 7 days after stroke compared with vehicle controls.

Conclusion Daily intranasal NBP treatment provides protective and neurogenic/angiogenic effects in the poststroke brain, accompanied with functional improvements after a focal ischaemic stroke in mice.

INTRODUCTION

Stroke is one of the most common causes of death and disability. Ischaemic stroke accounts for 85% of all strokes, which is the second leading cause of death worldwide after coronary heart disease. Ischaemic stroke occurs when cerebral blood flow is blocked followed by tissue damage and infarct formation in the brain. Intravenous thrombolysis and mechanical thrombectomy are Food and Drug Administration-approved treatments with limited time window for acute cerebral ischaemia. There is currently no approved treatment involving regenerative therapeutics for patients who had chronic stroke. Butyl phthalane was originally extracted from celery seeds. DL-3-N-butylyphthalide (NBP) was synthesised and approved by the National Medical Products Administration in China since 2002 for clinical treatments of patients who had a stroke. Basic and clinical research demonstrated protective effects of NBP after cerebral ischaemia, via the mechanisms of suppressing oxidative stress injury, mitochondrial damage, neuronal apoptosis and neuroinflammation. More investigations have shown beneficial effects of NBP for ischaemic stroke, Alzheimer’s disease, Parkinson’s disease and spinal cord injury. NBP also reduces oxidative stress-related damage, inhibits platelet aggregation, regulates energy metabolic homeostasis, improves microcirculation and reduces neurological deficits.

Using a focal ischaemic stroke model of mice, the current study tested the effect of chronic intranasal NBP delivery as a potential regenerative treatment for long-term recovery after ischaemic stroke.

MATERIALS AND METHODS

Animals

Male healthy C57BL/6 mice, 8–10 weeks old with a weight range of 25±5 g, were purchased from Jackson Laboratory and kept in the animal facility at Emory University. Animals were housed five per cage with free access to food and water. Room temperature ranged between 21°C and 24°C and had a relative humidity of 40%–70%.

Drug preparation

NBP was from Hebei Shiyou Group Enbipu Pharmaceutical. The drug was freshly prepared each time before administration...
and was prepared by diluting in vegetable oil (Kroger, Ohio). Bromodeoxyuridine (BrdU) (0.5% stock solution) was prepared in 0.9% sterile saline.

**Mouse model of focal cerebral ischaemia of the sensorimotor cortex**

A reproducible model of focal cerebral ischaemia targeting the right sensorimotor cortex in mice was established according to a previous publication. Briefly, mice were anaesthetised by 2% isoflurane. The distal middle cerebral artery (MCA) of the right side was permanently ligated, and the common carotid artery (CCA) on both sides was transiently blocked for 7 min. The sham operation group had the same procedures as the stroke group except that distal MCA or CCA was not ligated. Body temperature was maintained at 37°C.

**Drug administration**

Mice were randomly divided into a sham-operated group (sham), a vegetable oil vehicle group (stroke+oil) and an intranasal NBP group (stroke+NBP). The same volume (25 μL) of the vegetable oil vehicle or NBP (100 mg/kg) diluted in oil was administered to both nasals starting 1 hour after the stroke surgery to mimic acute on-site treatment conditions. After the first, daily intranasal administration of NBP was performed for a total of either 3 or 21 days. The dosage of NBP was selected based on our previous study on ischaemic stroke. Animals were sacrificed 3 or 21 days after stroke.

**Body weight monitoring**

The body weight of the control and NBP groups was measured and recorded every day and compared after stroke. The weight of both the vehicle group and the NBP group was plotted as before, during and after the stroke. All data are recorded at a fixed time point of the day in a double-blinded manner.

**Antibodies for protein expression analyses**

Immunohistochemical staining and/or western blotting used specific antibodies against vascular endothelial growth factor (VEGF) (Santa Cruz Biotechnology, California; Cat #Sc7269), endothelial nitric oxide synthase (eNOS) (Cell Signaling Technology, Massachusetts; Cat #30202), β-actin (Abcam, UK; Cat #ab49900), Glut-1 (Abcam; Cat #ab40084), NeuN (MilliporeSigma, Massachusetts; Cat #ABN78A4), BrdU (Abcam; Cat #ab6326), secondary antibody (Jackson ImmunoResearch Laboratories, Pennsylvania), OCT (Sakura Finetek, Japan) and fish gelatin (Sigma, Massachusetts). The 3M surgical adhesive (Fisher Scientific, New Hampshire) was used in the adhesive removal test.

Frozen microtome (Leica Microsystems, Germany) and fluorescence confocal microscope BX61 (Olympus, Japan) were used in brain sectioning and image experiments.

**Western blot analysis**

The cerebral cortical tissue of the infarcted region was dissected and placed into EP (Eppendorf tubes) tubes. Protein was extracted and the amount was quantified by bicinchoninic acid (BCA) method. A total of 40 μg protein for each sample was electrophoresed in a 10% sodium dodecyl sulfate (SDS)-PAGE gel, transferred to a Polyvinylidene fluoride (PVDF) membrane, and incubated with 5% Bovine Serum Albumin (BSA) solution in Tris-buffered saline (TBS) at room temperature for 1 hour and with primary antibodies in TBS at 4°C overnight. Secondary antibodies were added for 1 hour and washed in Tris-buffered saline, 0.1% Tween 20 (TBST) three times for 10 min each, for 5-bromo-4-chloro-3-indolyl phosphate (BCIP)- nitroblue tetrazolium (NBT)-based visualisation on a PVDF membrane.

**Immunohistochemical staining**

At the indicated times, mice were euthanised by carbon dioxide. Brains were immediately placed in dry ice, embedded in OCT embedding agent and stored at −80°C. A frozen microtome was then used to cut 10-micron section slices and stored at −80°C. Before the staining with primary antibodies, brain tissue sections were dried at room temperature, fixed with 10% formalin solution, washed three times in PBS for 10 min each, treated with 0.2% Triton X-100 in PBS, washed another three times with PBS for 10 min each and incubated with 3% fish gel for 1 hour at room temperature. Primary antibodies were diluted, mixed in PBS and incubated overnight at 4°C. The sections were washed three times with PBS for 10 min each and incubated with secondary antibodies in PBS at 37°C in the dark for 1 hour, washed another three times with PBS for 10 min each and mounted for fluorescence imaging. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining of cell death was performed using a TUNEL assay kit (Invitrogen, Carlsbad, California, USA) according to the manufacturer’s protocol.

**Local cerebral blood flow measurement**

Doppler cerebral blood flow metre (PeriFlux System 5000-PF5010 Laser Doppler Perfusion Monitoring (LDPM) unit, Sweden) was used to measure local cerebral blood flow (LCBF). The flow was recorded over the skull at the same location before, during and 3 days after ischaemia.

**Animal behaviour test**

The adhesive removal test was performed in double-blinded manner. Time is recorded when the mouse perceives the sticker attached onto the foot and removes it, as a measure of sensorimotor function. At 1, 3, 7, 14 and 21 days after stroke, functional recovery outcomes were measured.

**Statistical methods**

GraphPad Prism V.7.0 statistical software was used for the analyses. All data were presented in mean value or mean±SD for each group. Comparison between two groups was performed using Student’s t-test. Comparisons among the three groups were performed using one-way analysis of variance followed with Bonferroni correction. A threshold of p<0.05 was considered statistically significant.
RESULTS
Effects of NBP on LCBF and regulatory gene expression in the peri-infarct region
Stroke animals were given daily intranasal treatment of NBP from 1 hour after stroke until sacrifice (figure 1). Compared with the vehicle group, the LCBF was similarly reduced during ischaemic surgery and recovered at 3 days after stroke (figure 2A,B). NBP treatment showed a trend of better LCBF recovery but the effect was not significant (figure 2B). The observation was consistent with our measurement on the eNOS level in the peri-infarct region, showing no significant differences among all groups, although the NBP group displayed a trend towards a higher level of eNOS (figure 2C,D). On the other hand, the NBP treatment significantly increased VEGF at 3 days after stroke, suggesting that NBP might have an impact on poststroke regeneration (figure 2C,D).

Effects of NBP on body weight and sensorimotor functional recovery after stroke
The body weight of mice gradually recovered after stroke. There was in general no statistical difference between the vehicle and the NBP-treated groups, although the NBP group tended to have less body weight loss during the early days after stroke (figure 3A). The adhesive removal test measured the sensorimotor function associated with the stroke-damaged right sensorimotor cortex. At 1, 3 and 7 days after stroke, compared with the vehicle group, stroke mice that received intranasal NBP treatments performed significantly better in the removal of the adhesive. A spontaneous recovery was observed at 14 days after stroke in all stroke groups (figure 3B).

Protective and regenerative effects of NBP in the poststroke brain
At different days after stroke, mice were sacrificed for the analysis of vascular damage and neurovascular regeneration in the peri-infarct region. Three days after stroke, immunohistochemical staining revealed many Glut-1-positive vascular cells that were also TUNEL-positive, suggesting damaged vessels in the poststroke brain (figure 4A). Stroke animals that received NBP treatment, however, displayed significantly less TUNEL-positive vessels, suggesting a vascular protective effect (figure 4A). At 21 days after stroke, immunostaining showed significantly increased Glut-1 and BrdU double-positive cells in mice that received NBP treatments compared with stroke control mice (figure 4B,C). Meanwhile, there was also a marked increase in NeuN and BrdU double-positive cells with NBP treatment (figure 5A,B). These data demonstrated that NBP provides neuroprotective and proregenerative effects in the poststroke brain.

DISCUSSION
Intranasal drug delivery is a non-invasive and efficient method that allows bypassing the blood–brain barrier and entry into the brain. It is believed that drugs applied to the nasal mucosa are able to enter the brain regions through the olfactory nerve pathway, olfactory...
epithelium pathway and bloodstream, making it suitable for neurological treatments.26–28 We demonstrated that intranasal NBP treatment after brain injury improves neural regeneration.26 NBP increased the endogenous neural progenitor cell (NPC) migration to the ischaemic striatum and other injured brain regions.29 A mechanism study revealed that NBP increased the dentate gyrus NPC via regulation of PKA/BDNF/CREB and STAT3 signalling pathways to promote hippocampal neurogenesis.30 In a mouse model of Alzheimer’s disease, NBP activated BDNF/TrkB/CREB/Akt pathway and promoted neural regeneration.9

The current study reveals a vascular protective effect at 3 days after stroke by intranasally delivering NBP. Although this early protection did not translate to a significant increase in LCBF at the same time, it may be beneficial for LCBF and regeneration at later time points. Promoting neurovascular regeneration has been considered as an effective strategy for tissue repair after ischaemic stroke.31 32 VEGF is an angiogenic factor that stimulates blood vessel growth by inducing endothelial cell proliferation, migration and neovascularisation.33 34 The observed VEGF increase is consistent with other reports that NBP increased expressions of VEGF and basic fibroblast growth factor.23 35 36 Endothelial eNOS plays an important role in vascular reconstruction and vasodilatation in stroke brains. In the present study, the acute eNOS levels after stroke were not significantly changed, which was consistent with the LCBF data. On the other hand, eNOS can promote endothelial cell proliferation and migration, smooth muscle cell differentiation, arteriogenesis, collaterogenesis, and angiogenesis.37 38 It
**REFERENCES**

21. Jia J, Wei C, Liang J, et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischemic small vessel disease: a multicentre,


